1. Home
  2. Vaccines, Blood, & Biologics
  3. Vaccines
  4. NUVAXOVID
  1. Vaccines

NUVAXOVID

STN: 125817
Proper Name: COVID-19 Vaccine, Adjuvanted
Tradename: NUVAXOVID
Manufacturer: Sanofi Vaccines US, Inc

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

NUVAXOVID is approved for use in individuals who are:

  • 65 years of age and older, or
  • 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Some cartons of NUVAXOVID (2026-2027 Formula) do not identify the SARS-CoV-2 JN.1-descendent variant XFG on their labeling. 

  • Each 0.5 mL dose of NUVAXOVID (2026-2027 Formula) contains 5 mcg of recombinant spike glycoprotein (rS) of the SARS-CoV-2 JN.1-descendent variant XFG and 50 mcg Matrix-M adjuvant.
  • Package Insert and Patient Package Insert - NUVAXOVID
  • Demographic Subgroup Information – COVID-19 Vaccine, Adjuvanted (NUVAXOVID)
    Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Back to Top